Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
11,674
archived clinical trials in
Skin Cancer

Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Versus Carboplatin, Paclitaxel and Placebo in Patients With Unresectable Locally Advanced or Stage IV Melanoma
Status: Enrolling
Updated:  9/28/2015
Sydney West Area Health Service-Westmead Hospital
mi
from
Westmead,
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Versus Carboplatin, Paclitaxel and Placebo in Patients With Unresectable Locally Advanced or Stage IV Melanoma
Status: Enrolling
Updated: 9/28/2015
Sydney West Area Health Service-Westmead Hospital
mi
from
Westmead,
Click here to add this to my saved trials
Investigation of a Behavioral Substitute for Sunbathing
Investigation of a Behavioral Substitute for Sunbathing
Status: Enrolling
Updated:  9/29/2015
Univ of Massachusetts Med School
mi
from
Worcester, MA
Investigation of a Behavioral Substitute for Sunbathing
Investigation of a Behavioral Substitute for Sunbathing
Status: Enrolling
Updated: 9/29/2015
Univ of Massachusetts Med School
mi
from
Worcester, MA
Click here to add this to my saved trials
Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma
A Phase II Study of Combination Oral CC-5013 Lenalidomide (Revlimid™), Oral Sunitinib (Sutent™) and Low Dose Oral Metronomic Cyclophosphamide for the Treatment of Stage IV Ocular Melanoma
Status: Enrolling
Updated:  9/29/2015
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office
mi
from
Bethesda, MD
Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma
A Phase II Study of Combination Oral CC-5013 Lenalidomide (Revlimid™), Oral Sunitinib (Sutent™) and Low Dose Oral Metronomic Cyclophosphamide for the Treatment of Stage IV Ocular Melanoma
Status: Enrolling
Updated: 9/29/2015
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office
mi
from
Bethesda, MD
Click here to add this to my saved trials
Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers
Phase I Evaluation of Sodium Stibogluconate in Combination With Interferon α-2b Followed by Cisplatin, Vinblastine and Dacarbazine for Patients With Melanoma or Malignancies Potentially Responsive to SSG and/or Interferons
Status: Enrolling
Updated:  9/29/2015
Cleveland Clinic Taussig Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers
Phase I Evaluation of Sodium Stibogluconate in Combination With Interferon α-2b Followed by Cisplatin, Vinblastine and Dacarbazine for Patients With Melanoma or Malignancies Potentially Responsive to SSG and/or Interferons
Status: Enrolling
Updated: 9/29/2015
Cleveland Clinic Taussig Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain
A Phase II Study of Hypofractionated Highly Conformal Radiation With Helical Tomotherapy for Extra-Cranial Oligo
Status: Enrolling
Updated:  9/29/2015
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office
mi
from
Bethesda, MD
Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain
A Phase II Study of Hypofractionated Highly Conformal Radiation With Helical Tomotherapy for Extra-Cranial Oligo
Status: Enrolling
Updated: 9/29/2015
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office
mi
from
Bethesda, MD
Click here to add this to my saved trials
Melphalan and Whole-Body Hyperthermia in Treating Patients With Advanced Melanoma
Phase II Evaluation of IV Melphalan (L-PAM) and Whole Body Hyperthermia (WBH) for Malignant Melanoma
Status: Enrolling
Updated:  9/30/2015
University of Wisconsin Comprehensive Cancer Center
mi
from
Madison, WI
Melphalan and Whole-Body Hyperthermia in Treating Patients With Advanced Melanoma
Phase II Evaluation of IV Melphalan (L-PAM) and Whole Body Hyperthermia (WBH) for Malignant Melanoma
Status: Enrolling
Updated: 9/30/2015
University of Wisconsin Comprehensive Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
Fludarabine Followed By Adoptive Immunotherapy in Treating Patients With Stage IV Melanoma
Phase I Study to Evaluate the Safety of Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cell Clones Following Fludarabine Lymphodepletion for Patients With Metastatic Melanoma
Status: Enrolling
Updated:  9/30/2015
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Fludarabine Followed By Adoptive Immunotherapy in Treating Patients With Stage IV Melanoma
Phase I Study to Evaluate the Safety of Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cell Clones Following Fludarabine Lymphodepletion for Patients With Metastatic Melanoma
Status: Enrolling
Updated: 9/30/2015
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Lapatinib in Stage IV Melanoma With ERBB4 Mutations
A Phase II Study of Lapatinib for the Treatment of Stage IV Melanoma Harboring ERBB4 Mutations
Status: Enrolling
Updated:  10/1/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Lapatinib in Stage IV Melanoma With ERBB4 Mutations
A Phase II Study of Lapatinib for the Treatment of Stage IV Melanoma Harboring ERBB4 Mutations
Status: Enrolling
Updated: 10/1/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells
A Feasibility and Safety Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells in Patients With Metastatic and/or Unresectable Melanoma
Status: Enrolling
Updated:  10/1/2015
Medical University of South Carolina
mi
from
Charleston, SC
Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells
A Feasibility and Safety Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells in Patients With Metastatic and/or Unresectable Melanoma
Status: Enrolling
Updated: 10/1/2015
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Vaccine Therapy in Treating Patients With Stage IV or Recurrent Malignant Melanoma
A Phase I/II Trial Testing Mart-1 Genetic Immunization In Malignant Melanoma
Status: Enrolling
Updated:  10/1/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Vaccine Therapy in Treating Patients With Stage IV or Recurrent Malignant Melanoma
A Phase I/II Trial Testing Mart-1 Genetic Immunization In Malignant Melanoma
Status: Enrolling
Updated: 10/1/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma
Phase II Trial Of Interferon-B In Patients With Metastatic Cutaneous Melanoma And Metastatic Ocular Melanoma
Status: Enrolling
Updated:  10/1/2015
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma
Phase II Trial Of Interferon-B In Patients With Metastatic Cutaneous Melanoma And Metastatic Ocular Melanoma
Status: Enrolling
Updated: 10/1/2015
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Nuclear and Near-Infrared (NIR) Imaging in Melanoma
Diagnostic Nodal Staging for Melanoma With Nuclear and Near-Infrared (NIR) Molecular Optical Imaging
Status: Enrolling
Updated:  10/5/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Nuclear and Near-Infrared (NIR) Imaging in Melanoma
Diagnostic Nodal Staging for Melanoma With Nuclear and Near-Infrared (NIR) Molecular Optical Imaging
Status: Enrolling
Updated: 10/5/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated:  10/6/2015
UAB Comprehensive Cancer Center
mi
from
Birmingham, AL
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated: 10/6/2015
UAB Comprehensive Cancer Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated:  10/6/2015
St. Joseph Medical Center
mi
from
Bloomington, IL
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated: 10/6/2015
St. Joseph Medical Center
mi
from
Bloomington, IL
Click here to add this to my saved trials
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated:  10/6/2015
Graham Hospital
mi
from
Canton, IL
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated: 10/6/2015
Graham Hospital
mi
from
Canton, IL
Click here to add this to my saved trials
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated:  10/6/2015
Memorial Hospital
mi
from
Carthage, IL
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated: 10/6/2015
Memorial Hospital
mi
from
Carthage, IL
Click here to add this to my saved trials
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated:  10/6/2015
Decatur Memorial Hospital Cancer Care Institute
mi
from
Decatur, IL
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated: 10/6/2015
Decatur Memorial Hospital Cancer Care Institute
mi
from
Decatur, IL
Click here to add this to my saved trials
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated:  10/6/2015
Eureka Community Hospital
mi
from
Eureka, IL
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated: 10/6/2015
Eureka Community Hospital
mi
from
Eureka, IL
Click here to add this to my saved trials
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated:  10/6/2015
Galesburg Clinic, PC
mi
from
Galesburg, IL
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated: 10/6/2015
Galesburg Clinic, PC
mi
from
Galesburg, IL
Click here to add this to my saved trials
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated:  10/6/2015
Mason District Hospital
mi
from
Havana, IL
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated: 10/6/2015
Mason District Hospital
mi
from
Havana, IL
Click here to add this to my saved trials
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated:  10/6/2015
Hinsdale Hematology Oncology Associates
mi
from
Hinsdale, IL
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated: 10/6/2015
Hinsdale Hematology Oncology Associates
mi
from
Hinsdale, IL
Click here to add this to my saved trials
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated:  10/6/2015
McDonough District Hospital
mi
from
Macomb, IL
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated: 10/6/2015
McDonough District Hospital
mi
from
Macomb, IL
Click here to add this to my saved trials
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated:  10/6/2015
BroMenn Regional Medical Center
mi
from
Normal, IL
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated: 10/6/2015
BroMenn Regional Medical Center
mi
from
Normal, IL
Click here to add this to my saved trials
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated:  10/6/2015
OSF Saint Elizabeth Medical Center
mi
from
Ottawa, IL
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated: 10/6/2015
OSF Saint Elizabeth Medical Center
mi
from
Ottawa, IL
Click here to add this to my saved trials
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated:  10/6/2015
Cancer Treatment Center at Pekin Hospital
mi
from
Pekin, IL
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated: 10/6/2015
Cancer Treatment Center at Pekin Hospital
mi
from
Pekin, IL
Click here to add this to my saved trials
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated:  10/6/2015
Methodist Medical Center of Illinois
mi
from
Peoria, IL
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated: 10/6/2015
Methodist Medical Center of Illinois
mi
from
Peoria, IL
Click here to add this to my saved trials
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated:  10/6/2015
OSF St. Francis Medical Center
mi
from
Peoria, IL
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated: 10/6/2015
OSF St. Francis Medical Center
mi
from
Peoria, IL
Click here to add this to my saved trials
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated:  10/6/2015
Proctor Hospital
mi
from
Peoria, IL
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated: 10/6/2015
Proctor Hospital
mi
from
Peoria, IL
Click here to add this to my saved trials
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated:  10/6/2015
Illinois Valley Community Hospital
mi
from
Peru, IL
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated: 10/6/2015
Illinois Valley Community Hospital
mi
from
Peru, IL
Click here to add this to my saved trials
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated:  10/6/2015
Perry Memorial Hospital
mi
from
Princeton, IL
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated: 10/6/2015
Perry Memorial Hospital
mi
from
Princeton, IL
Click here to add this to my saved trials
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated:  10/6/2015
Swedish-American Regional Cancer Center
mi
from
Rockford, IL
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated: 10/6/2015
Swedish-American Regional Cancer Center
mi
from
Rockford, IL
Click here to add this to my saved trials
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated:  10/6/2015
Borgess Medical Center
mi
from
Kalamazoo, MI
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated: 10/6/2015
Borgess Medical Center
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated:  10/6/2015
Bronson Methodist Hospital
mi
from
Kalamazoo, MI
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated: 10/6/2015
Bronson Methodist Hospital
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated:  10/6/2015
West Michigan Cancer Center
mi
from
Kalamazoo, MI
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated: 10/6/2015
West Michigan Cancer Center
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated:  10/6/2015
Jean and Milton Cooper Cancer Center at Summa Akron City Hospital
mi
from
Akron, OH
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated: 10/6/2015
Jean and Milton Cooper Cancer Center at Summa Akron City Hospital
mi
from
Akron, OH
Click here to add this to my saved trials
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated:  10/6/2015
Aultman Cancer Center at Aultman Hospital
mi
from
Canton, OH
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated: 10/6/2015
Aultman Cancer Center at Aultman Hospital
mi
from
Canton, OH
Click here to add this to my saved trials
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated:  10/6/2015
MetroHealth Cancer Care Center at MetroHealth Medical Center
mi
from
Cleveland, OH
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated: 10/6/2015
MetroHealth Cancer Care Center at MetroHealth Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated:  10/6/2015
West Virginia University Health Sciences Center - Charleston
mi
from
Charleston, WV
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated: 10/6/2015
West Virginia University Health Sciences Center - Charleston
mi
from
Charleston, WV
Click here to add this to my saved trials
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated:  10/6/2015
Gundersen Lutheran Center for Cancer and Blood
mi
from
La Crosse, WI
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated: 10/6/2015
Gundersen Lutheran Center for Cancer and Blood
mi
from
La Crosse, WI
Click here to add this to my saved trials
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated:  10/6/2015
Lakeland Regional Cancer Center at Lakeland Regional Medical Center
mi
from
Lakeland, FL
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated: 10/6/2015
Lakeland Regional Cancer Center at Lakeland Regional Medical Center
mi
from
Lakeland, FL
Click here to add this to my saved trials
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated:  10/6/2015
Community Cancer Center
mi
from
Normal, IL
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated: 10/6/2015
Community Cancer Center
mi
from
Normal, IL
Click here to add this to my saved trials
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated:  10/6/2015
CCOP - Illinois Oncology Research Association
mi
from
Peoria, IL
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated: 10/6/2015
CCOP - Illinois Oncology Research Association
mi
from
Peoria, IL
Click here to add this to my saved trials
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated:  10/6/2015
Oncology Hematology Associates of Central Illinois, PC - Peoria
mi
from
Peoria, IL
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated: 10/6/2015
Oncology Hematology Associates of Central Illinois, PC - Peoria
mi
from
Peoria, IL
Click here to add this to my saved trials
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated:  10/6/2015
UPMC Cancer Centers
mi
from
Pittsburgh, PA
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor
Status: Enrolling
Updated: 10/6/2015
UPMC Cancer Centers
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes
Phase I/II Study of Metastatic Cancer That Expresses MAGE-A3/12 Using Lymphodepleting Conditioning Followed by Infusion of Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes
Status: Enrolling
Updated:  10/6/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes
Phase I/II Study of Metastatic Cancer That Expresses MAGE-A3/12 Using Lymphodepleting Conditioning Followed by Infusion of Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes
Status: Enrolling
Updated: 10/6/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma
Phase II Study of Metastatic Melanoma Using a Chemoradiation Lymphodepleting Conditioning Regimen Followed by Infusion of Anti-Mart-1 and Anti-gp100 TCR-Gene Engineered Lymphocytes and Peptide Vaccines
Status: Enrolling
Updated:  10/6/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma
Phase II Study of Metastatic Melanoma Using a Chemoradiation Lymphodepleting Conditioning Regimen Followed by Infusion of Anti-Mart-1 and Anti-gp100 TCR-Gene Engineered Lymphocytes and Peptide Vaccines
Status: Enrolling
Updated: 10/6/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M...
Prospective Randomized Comparative Study of Cell Transfer Therapy Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-dose Aldesleukin in Metastatic Melanoma
Status: Enrolling
Updated:  10/6/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M...
Prospective Randomized Comparative Study of Cell Transfer Therapy Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-dose Aldesleukin in Metastatic Melanoma
Status: Enrolling
Updated: 10/6/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer
Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer
Status: Enrolling
Updated:  10/6/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer
Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer
Status: Enrolling
Updated: 10/6/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma
Phase II Study of Lymphocytes Generated With Engineered Cells for Costimulation Enhancement in Patients With Metastatic Melanoma Following Lymphodepletion
Status: Enrolling
Updated:  10/6/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma
Phase II Study of Lymphocytes Generated With Engineered Cells for Costimulation Enhancement in Patients With Metastatic Melanoma Following Lymphodepletion
Status: Enrolling
Updated: 10/6/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Safety and Efficacy Study of DCVax-Direct in Solid Tumors
A PHASE I/II CLINICAL TRIAL EVALUATING DCVax-Direct, AUTOLOGOUS ACTIVATED DENDRITIC CELLS FOR INTRATUMORAL INJECTION, IN PATIENTS WITH SOLID TUMORS
Status: Enrolling
Updated:  10/6/2015
Orlando Health
mi
from
Orlando, FL
Safety and Efficacy Study of DCVax-Direct in Solid Tumors
A PHASE I/II CLINICAL TRIAL EVALUATING DCVax-Direct, AUTOLOGOUS ACTIVATED DENDRITIC CELLS FOR INTRATUMORAL INJECTION, IN PATIENTS WITH SOLID TUMORS
Status: Enrolling
Updated: 10/6/2015
Orlando Health
mi
from
Orlando, FL
Click here to add this to my saved trials